ARCHIVES

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Simone Retires From Academic Medicine, But Plans To Remain Active In Advisory Roles.

September 7, 2001

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

April 27, 2001

In Brief: Georgetown Professor Heads Cancer Therapy Evaluation Program; NCI-VA Branch Abolished

September 7, 1979

Blinatumomab Shows Response In Adults with Refractory ALL

May 25, 2012

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

September 27, 2013

Daniel Hayes Elected President of ASCO

December 12, 2014